Pilot Study of Avelumab in Thymic Epithelial Tumors

Division Of Basic Sciences - Nci

Investigators

Linked publications, trials & patents

Abstract

As of July 2023, 41 subjects have enrolled in the study (22 thymoma; 19 thymic carcinoma). All subjects are evaluable for response. Among the subjects with thymoma, 2 had confirmed partial response and 20 had stable disease. Among subjects with thymic carcinoma, 1 had a confirmed partial response, 14 had stable disease and 3 had progressive disease. All subjects were assessed for adverse events. Immune-related adverse events (irAEs) related to treatment were observed in 14 of 22 subjects with thymoma and in 8 of 19 subjects with thymic carcinoma. Immune correlative studies are being performed in parallel. Preliminary results show the presence of lower levels of B cells and plasmacytoid dendritic cells at baseline among responders and higher levels of CD4 cells and lower NK-T cells at baseline among subjects that develop irAEs.